Morgan Stanley analyst Michael Ulz upgraded Akero Therapeutics to Overweight from Equal Weight with a $65 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AKRO:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Officer of Akero Therapeutics Yale sells $253K in company shares
- Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics
- Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH
- Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones